Intranasal H1N1 vaccine enters Phase II trials
This article was originally published in Scrip
Executive Summary
Avir Green Hills Biotechnology, a Vienna-based biotech company, has started a 48-patient Phase II clinical trial of deltaFLU, an intranasal H1N1 influenza vaccine. It plans a separate Phase II study in patients above 65 years of age later in the year.